

Doug Abel

Doug's career has been focused on the launch of cutting-edge, highly disruptive products in the medical device, biotechnology, and specialty pharmaceutical arenas. The majority of his career has been focused on aesthetics and dermatology and on launching new products and companies within those specialties. Over the past 30 years he has had leadership roles in the clinical development and launch of BOTOX® (both aesthetic and neurologic applications), bringing the first biologic products to dermatology, returning thread lifts to the US market with a novel, resorbable product, and is now focused on the development of the next generation of dermal fillers/injectable implants and minimally invasive aesthetic breast surgery.

Doug currently serves as the President & CEO of Advanced Aesthetic Technologies, developing the agarose based sub-dermal filler Algeness®. He is also the Chairman of RevoAesthetics LLC, a company focused on revolutionizing the approach to aesthetic breast surgery via the development of minimally invasive technologies and techniques. Prior to his current positions, Doug served as President of Sinclair North America and was responsible for the launch of Sinclair's first product in the US, Silhouette InstaLift™, as well as the development and commercialization of Sinclair's full product pipeline in the US and Canada. He earlier led the initial efforts to bring BOTOX® to the global aesthetic community while with Allergan and subsequently spearheaded Biogen's program to bring the first biologic approved for psoriasis to market. He has also held senior leadership positions at several startup dermatology and aesthetic companies. Doug's experience spans US and global leadership in product launch, sales and marketing, product development, and executive level oversight of all stages of the regulatory approval process, manufacturing, and finance. He holds a BA in Chemistry from Lafayette College and an MBA from Temple University.